|Bid||2.3700 x 3000|
|Ask||2.5500 x 4000|
|Day's Range||2.3800 - 2.4900|
|52 Week Range||1.8000 - 5.6100|
|Beta (5Y Monthly)||2.22|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The big shareholder groups in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) have power over the company. Institutions often...
What happened Shares of Ziopharm Oncology (NASDAQ: ZIOP) were zooming 13.1% higher as of 3:50 p.m. EDT on Monday. The big jump came after the company announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (also known as Controlled IL-12) in treating diffuse intrinsic pontine glioma (DIPG), a type of brain tumor.
If you are looking for the best ideas for your portfolio you may want to consider some of Miller Value Partners top stock picks. Miller Value Partners, an investment management firm, is bullish on Ziopharm Oncology Inc (NASDAQ:ZIOP) stock. In its Opportunity Equity Q2 2019 investor letter – you can download a copy here – […]